Affordable Access

deepdyve-link deepdyve-link
Publisher Website

Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selection.

Authors
Type
Published Article
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
Publication Date
Volume
19
Issue
18
Pages
5227–5239
Identifiers
DOI: 10.1158/1078-0432.CCR-13-0489
PMID: 23935036
Source
Medline
License
Unknown

Abstract

This study shows a discriminatory signature comprising mesothelin, FLT4, AGP, and CA-125 as potentially identifying those patients with EOC more likely to benefit from bevacizumab. These results require validation in further patient cohorts.

Statistics

Seen <100 times